



PPL/CS/SE/927/2010-11
November 12, 2010

To

The Bombay Stock Exchange Limited

Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001

Kind Attn.: Mr. Subramaniam

The National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai 400 051

Kind Attn.: Mr. Hari K.

Dear Sir,

**Sub: Submission of un-audited financial results for the quarter ended
30.09.2010**

Please find enclosed herewith the un-audited financial results of the Company for quarter ended on 30th September, 2010 duly taken on record by the Board of Directors of the Company at their meeting held on 12th November, 2010.

This is for the information of the Exchange and members thereof.

Kindly take the same on record and oblige.

Thanking You

Yours Sincerely

For PLETHICO PHARMACEUTICALS LIMITED


AMRISH CHOURASIA
COMPANY SECRETARY



Encl. : As above

PLETHICO PHARMACEUTICALS LIMITED

Regd. Office : A.B. Road, Manglia - 453 771, Dist. - Indore (M.P.), +91-731-2806275, +91-731-2806271
Admn. Office : 37, Industrial Estate, Pologround, Indore 452 015 (M.P.) Tel.: +91-731-2422881/84
Fax : +91-731-2420938, 2421309
Corporate Office : Sabnam House, Plot No. A-15/16, Central Cross Road-B, M.I.D.C., Andheri (East),
Mumbai 400 093, INDIA Tel.: +91-22-66988301/302, Fax : +91-22-66988330/+91-22-66988300
Website : www.plethico.com **E-mail :** info@plethico.com, corporate@plethico.com


UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2010											Rs. In Lacs
Sr. No.	Particulars	Independent Financials					Consolidated Financials				
		3 Month Ended		9 Month Ended		Year Ended	3 Month Ended		9 Month Ended		Year Ended
		30.09.2010	30.09.2009	30.09.2010	30.09.2009	31.12.2009	30.09.2010	30.09.2009	30.09.2010	30.09.2009	31.12.2009
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Net Sales/Income from Operations	9748.93	10917.40	32174.35	34252.22	46554.75	41608.23	33286.70	110475.23	86579.52	124307.50
2	Other Incomes	(1.47)	3.08	31.78	353.50	393.74	13.13	3.08	101.83	353.50	544.64
3	Total Income (1+2)	9747.46	10920.48	32206.13	34605.72	46948.49	41621.36	33289.78	110577.06	86933.03	124852.14
4	Expenditure										
	a) (Increase) / Decrease in Stock in trade & work in progress	(156.32)	28.56	(167.30)	38.19	(59.25)	(1607.92)	(23.44)	(1685.62)	587.22	(1758.65)
	b) Consumption of Raw Materials	3635.26	4991.16	16078.38	15361.73	22177.15	13396.96	10561.16	30112.86	25026.60	30094.15
	c) Purchase of Finished goods	63.06	19.88	195.43	281.22	518.83	9164.56	2020.88	24682.66	10369.16	27137.75
	d) Employees Cost	767.70	630.19	2208.55	1907.30	2584.24	2430.30	2614.60	7368.60	8086.10	11013.08
	e) Depreciation/Amortization	228.01	224.30	682.02	602.32	811.42	528.71	465.80	1441.51	1347.33	1855.32
	f) Other Expenditure	2461.76	2715.81	5619.90	7277.49	8926.93	8707.96	11392.90	24559.06	27908.87	34105.27
	Total Expenditure	6999.47	8609.90	24616.98	25468.25	34959.32	32620.57	27031.90	86479.07	73325.29	102446.92
5	Interest (Net)	833.69	643.24	2159.98	2146.76	2881.54	863.29	677.34	2254.39	2227.01	3005.24
6	Exceptional items	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00
7	Profit (+)/ Loss (-) from Ordinary Activities before tax (3) - (4+5+6)	1914.30	1667.34	5429.17	6990.71	9107.63	8137.50	5580.54	21843.60	11380.72	19399.98
8	Tax expense	905.16	10.20	1035.71	89.30	38.16	817.36	(236.60)	1246.16	(720.47)	(657.24)
9	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (7-8)	1009.14	1657.14	4393.46	6901.41	9069.47	7320.14	5817.14	20597.44	12101.19	20057.22
10	Extra-Ordinary Items (net of tax expense)	1132.50	(150.00)	1196.25	454.00	1635.00	1132.50	(150.00)	1196.30	454.00	1635.00
11	Net Profit (+)/Loss(-)for the period (9 - 10)	2141.64	1507.14	5589.71	7355.41	10704.47	8452.64	5667.14	21793.74	12555.19	21692.22
12	Paid-up equity share capital (Nominal Value – Rs. 10/- each)	3406.67	3406.67	3406.67	3406.67	3406.67	3406.67	3406.67	3406.67	3406.67	3406.67
13	Reserves excluding Revaluation reserves as per balance sheet of previous accounting year	-	-	-	-	64405.95	-	-	-	-	-
14	Earning Per Share (EPS)										
	(a) EPS before Extra-Ordinary items for the period, for the year to date and for the previous year (not to be annualized) (Rs.)	2.96	4.86	12.90	20.26	26.62	21.49	17.08	60.46	35.52	58.88
	Basic										
	Diluted	2.51	4.13	10.95	17.19	22.60	18.24	14.49	51.32	30.15	49.97
	(b) EPS after Extra-Ordinary items for the period, for the year to date and for the previous year (not to be annualised) (Rs.)	6.29	4.42	16.41	21.59	31.42	24.81	16.64	63.97	36.85	63.68
	Basic										
	Diluted	5.34	3.75	13.93	18.33	26.67	21.06	14.12	54.30	31.28	54.04
15	Public Shareholding										
	a) Number of equity shares	4426667	4426667	4426667	4426667	4426667	4426667	4426667	4426667	4426667	4426667
	b) Percentage of Shareholding	12.99%	12.99%	12.99%	12.99%	12.99%	12.99%	12.99%	12.99%	12.99%	12.99%

16	Promoter and Promoter Group Shareholding :										
	a) Pledged/Encumbered										
	- Number of shares	25436865	19475000	-	-	23910000	-		-		
	-Percentage of Shares (as a % of total shareholding of promoter and promoter group)	85.82%	65.71%	-	-	80.67%	-		-		
	- Percentage of shares (as a % of the total share capital of the Company)	74.67%	57.17%	-	-	70.19%	-		-		
	b) Non-encumbered			-	-		-		-		
	- Number of shares	4203135	10165000	-	-	5730000.00	-		-		
	-Percentage of Shares (as a % of total shareholding of promoter and promoter group)	14.18%	34.29%	-	-	19.33%	-		-		
	- Percentage of shares (as a % of the total share capital of the Company)	12.34%	29.84%	-	-	16.82%	-		-		

1. The above unaudited financial results for the quarter ended on 30th Sep,2010 were approved at the meeting of the Board of Directors held on 12th Nov, 2010, after being approved and recommended by the Audit Committee.
2. The Statutory Auditors have carried out a limited review of the results for the quarter ended on 30th Sep, 2010.
3. The Company is engaged in a single segment viz. Pharmaceuticals which is governed by the same set of risks and returns, therefore the Accounting Standard (AS-17) on "Segment Reporting" issued by ICAI, is not applicable.
4. Figures of the previous quarter wherever necessary have been regrouped and reclassified to confirm to those of the current quarter.
5. The cost of Packing materials has been included in other expenditure, whereas Directors' remuneration has been included in the employees cost.
6. The consolidated financial results comprise results of its wholly owned subsidiary Plethico International Ltd and Plethico Global Holdings B.V., Netherlands having different step-down subsidiaries particularly Plethico US Holding KFT Hungary, Natrol Inc., USA. and Natrol Global UAE., The financial results of subsidiary companies have been regrouped and / or rearranged wherever necessary due to Indian GAAP.
7. Extra-ordinary items is related to unrealized exchange Gain of Rs. 1132.50 Lacs arising on account of restatement of outstanding Foreign Currency Convertible Bonds (FCCB) at the rate prevailing at the end of quarter.
8. Provision on account of premium payable on redemption of FCCB has been made amounting to Rs. 549.81 Lacs during the quarter ended 30.09.2010 out of Share Premium Reserve.
9. Details of investors complaints for the quarter ended: Unresolved at the beginning of the quarter - Nil, Received during the quarter - 5, Disposed off during the quarter - 5, Unresolved at the end of the quarter - Nil.

Date : 12-11-2010
Place : Indore

For PLETHICO PHARMACEUTICALS LIMITED



[Signature]
SHASHIKANT PATEL
CHAIRMAN CUM MANAGING DIRECTOR